1260666-80-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoroisoindolin-1-one is used as a key intermediate in the synthesis of pharmaceutical drugs for its ability to contribute to the development of biologically active compounds. Its unique structure allows for the creation of new drug candidates with potential therapeutic properties.
Used in Natural Product Synthesis:
In the field of natural product synthesis, 5-Fluoroisoindolin-1-one serves as a valuable building block, enabling the production of complex organic molecules that can be found in nature and have potential applications in medicine and other industries.

Upstream product

• 84194-36-5 2-chloro-4-fluorobenzaldehyde 
• 127510-96-7 2-cyano-4-fluorobenzoic acid methyl ester 
• 85953-29-3 methyl 2-chloro-4-fluorobenzoate 
• 653-92-9 methyl 2-bromo-4-fluorobenzoate 
• 100-82-3 (3-fluorophenyl)methanamine 
• 201230-82-2 carbon monoxide 

Downstream Products

• 1361386-68-6 2-bromo-6-(5-(ethyl(methyl)amino)-1-oxoisoindolin-2-yl)benzyl acetate 
• 1361386-69-7 2-(5-(ethyl(methyl)amino)-1-oxoisoindolin-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1605312-66-0 (2R,5S)-4-{2-[3-(2,4-difluoro-benzyl)-7,7-dimethyl-6,7-dihydro-pyrrolo[3,2-c]pyridazin-5-yl]-2-oxo-ethyl}-5-(5-fluoro-1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-2-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1036389-90-8 6-amino-5-fluoro-isoindolin-1-one 

Relevant academic research and scientific papers

Palladium-Catalyzed Direct C-H Carbonylation of Free Primary Benzylamines: A Synthesis of Benzolactams

A protocol for palladium-catalyzed C-H carbonylation of readily available free primary benzylamines using NH2 as the chelating group under an atmospheric pressure of CO has been achieved, providing a general, atom- and step-economic approach to

DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.

BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY

The invention relates to new bicyclic heterocycle compounds of formula (I): (Formula (I)), pharmaceutical compositions comprising said compounds and to use of said compounds in the treatment of diseases, e.g. cancer.

PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.